Shanghai RAAS Blood Products Co., Ltd.
ISIN CNE100000C31
|WKN A0RPGQ
Market cap (in EUR)
5,623.65 m
Country
China
Sector
Healthcare
Dividend yield
0.98%
Overview
Description
Shanghai RAAS Blood Products Co., Ltd. engages in the research, development, production, and sale of blood products. It provides human albumin, intravenous injection of human immunoglobulin, coagulation factor products, vaccines, diagnostic reagents, and testing services. The company was founded by Kieu Hoang on October 29, 1988 and is headquartered in Shanghai, China.
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals China
Financials
Key metrics
| Market capitalisation, EUR | 5,623.65 m |
| EPS, EUR | 0.04 |
| P/B ratio | 1.39 |
| P/E ratio | 22.54 |
| Dividend yield | 0.98% |
Income statement (2024)
| Revenue, EUR | 1,043.90 m |
| Net income, EUR | 281.78 m |
| Profit margin | 26.99% |
What ETF is Shanghai RAAS Blood Products Co., Ltd. in?
There are 64 ETFs which contain Shanghai RAAS Blood Products Co., Ltd.. All of these ETFs are listed in the table below. The ETF with the largest weighting of Shanghai RAAS Blood Products Co., Ltd. is the Xtrackers Harvest CSI 300 UCITS ETF 1D.
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.
